We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




World’s Largest Image-Based AI Models for Digital Pathology and Oncology to Fight Cancer

By LabMedica International staff writers
Posted on 19 Sep 2023
Print article
Image: Paige’s advanced digital pathology and AI software transform the way pathologists work and labs operate (Photo courtesy of Paige)
Image: Paige’s advanced digital pathology and AI software transform the way pathologists work and labs operate (Photo courtesy of Paige)

Two major companies have come together with the goal of revolutionizing cancer diagnosis and treatment by creating the world's most extensive image-based AI models in the fields of digital pathology and oncology.

Paige (New York, NY, USA) and Microsoft (Redmond, WA, USA) are collaborating to build the world's biggest AI model based on images. Paige has already built the first Large Foundation Model, which incorporates over a billion images from half a million pathology slides covering various types of cancer. Together with Microsoft, Paige is working on a new AI model that is far larger than any other image-based AI model currently in existence. Designed with billions of parameters, this model aims to capture the subtle complexities of cancer. This model is expected to serve as the cornerstone for future clinical tools and computational biomarkers that could reshape the fields of oncology and pathology.

For the next stage of this development, Paige plans to add up to four million digitized microscope slides from its enormous, petabyte-scale collection of clinical data, covering multiple cancer types. To make this happen, Paige will leverage Microsoft's advanced supercomputing capabilities to train this colossal AI model. Once ready, the technology is set to be deployed to hospitals and labs worldwide via Microsoft's Azure platform.

“Paige has been at the forefront of innovation since its inception, and by combining Microsoft’s expertise and enormous compute power with Paige’s deep expertise in AI, technology, and digital pathology, we strongly believe we will significantly advance the state-of-the-art in cancer imaging. Through the development of this model, we will help improve the lives of the millions of people who are affected by cancer every day,” said Razik Yousfi, SVP of Technology at Paige.

“Paige technology already goes beyond what is humanly possible today and helps physicians deliver better cancer care with AI support. By realizing the potential of generative AI at unprecedented scale, the Paige model collaboration with Microsoft is a milestone in the history of oncology. It opens a window into the microscopic world with extraordinary fidelity, allowing for not only much higher accuracy but completely novel capabilities,” said Thomas Fuchs, Dr.Sc., Founder and Chief Scientist of Paige.

“By combining Microsoft’s world-class research and cloud infrastructure with Paige’s deep expertise and large-scale data, we are creating new AI models that will enable unprecedented insights into the pathology of cancer,” said Desney Tan, Vice President and Managing Director, Microsoft Health Futures, “Unleashing the power of AI is a game changer in advancing healthcare to improve lives.”

Related Links:
Paige
Microsoft

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.